See more : Chlitina Holding Limited (4137.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Alto Ingredients, Inc. (ALTO) Income Statement Analysis – Financial Results
- American Films, Inc. (AMFL) Income Statement Analysis – Financial Results
- Nexteligent Holdings, Inc. (NXGT) Income Statement Analysis – Financial Results
- Petróleo Brasileiro S.A. – Petrobras (PBR-A) Income Statement Analysis – Financial Results
- Golden Lake Exploration Inc. (GOLXF) Income Statement Analysis – Financial Results
Simulations Plus, Inc. (SLP)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.simulations-plus.com
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M | 29.67M | 24.14M | 19.97M | 18.31M | 11.46M | 10.07M | 9.45M | 11.72M | 10.71M | 9.14M | 8.97M | 8.86M | 5.86M | 4.75M | 5.21M | 5.48M | 4.44M | 3.91M | 3.63M | 3.47M | 2.65M | 2.49M | 2.60M |
| Cost of Revenue | 26.86M | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M | 7.99M | 6.31M | 4.60M | 4.32M | 1.63M | 1.65M | 1.51M | 2.88M | 2.55M | 2.32M | 2.10M | 2.08M | 1.60M | 1.51M | 1.56M | 1.54M | 1.46M | 1.56M | 1.16M | 1.65M | 1.76M | 1.25M | 1.20M |
| Gross Profit | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M | 21.67M | 17.83M | 15.37M | 14.00M | 9.83M | 8.42M | 7.94M | 8.84M | 8.17M | 6.82M | 6.87M | 6.78M | 4.25M | 3.24M | 3.65M | 3.95M | 2.99M | 2.35M | 2.47M | 1.82M | 889.25K | 1.24M | 1.40M |
| Gross Profit Ratio | 61.63% | 80.48% | 79.92% | 77.19% | 74.39% | 73.43% | 73.05% | 73.87% | 76.96% | 76.43% | 85.79% | 83.65% | 84.02% | 75.44% | 76.23% | 74.61% | 76.58% | 76.49% | 72.60% | 68.27% | 70.09% | 71.96% | 67.23% | 60.08% | 67.98% | 52.45% | 33.62% | 49.77% | 53.85% |
| Research & Development | 5.75M | 4.50M | 3.21M | 4.05M | 2.97M | 2.50M | 1.79M | 1.37M | 1.45M | 1.33M | 952.77K | 802.37K | 947.56K | 935.20K | 969.87K | 1.11M | 990.49K | 814.95K | 445.25K | 524.56K | 515.02K | 379.63K | 382.14K | 354.09K | 299.88K | 218.51K | 390.45K | 133.02K | 100.00K |
| General & Administrative | 22.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M | 6.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 131.78K | 38.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.27M | 34.72M | 24.97M | 20.57M | 16.36M | 11.80M | 9.58M | 8.20M | 6.69M | 6.81M | 4.44M | 3.55M | 3.38M | 4.31M | 4.33M | 3.90M | 3.70M | 3.46M | 2.97M | 2.42M | 2.51M | 2.30M | 2.11M | 2.20M | 2.14M | 2.31M | 2.68M | 2.28M | 1.20M |
| Other Expenses | 0.00 | 2.97M | 204.00K | 0.00 | 14.30B | 14.30B | 8.14B | 0.00 | 0.00 | 0.00 | 0.00 | 35.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.15K | 0.00 | 0.00 | 0.00 | 100.00K |
| Operating Expenses | 37.02M | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M | 11.37M | 9.57M | 8.14M | 8.14M | 5.39M | 4.35M | 4.33M | 5.24M | 5.30M | 5.01M | 4.69M | 4.27M | 3.42M | 2.95M | 3.02M | 2.68M | 2.49M | 2.55M | 2.70M | 2.53M | 3.07M | 2.41M | 1.40M |
| Cost & Expenses | 63.88M | 50.85M | 39.00M | 35.21M | 29.98M | 23.32M | 19.37M | 15.87M | 12.74M | 12.46M | 7.02M | 6.00M | 5.84M | 8.12M | 7.84M | 7.33M | 6.79M | 6.36M | 5.02M | 4.46M | 4.58M | 4.22M | 3.94M | 4.12M | 3.87M | 4.18M | 4.83M | 3.66M | 2.60M |
| Interest Income | 4.38M | 4.13M | 717.00K | 201.00K | 29.47K | 33.52K | 27.12K | 15.86K | 18.01K | 17.94K | 31.44K | 49.49K | 89.27K | 91.86K | 101.55K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 717.00K | 22.00K | 0.00 | 109.08K | 153.03K | 38.19K | 18.01K | 17.94K | 31.44K | 49.49K | 3.00 | 118.00 | 1.05K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.67M | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M | 2.72M | 2.14M | 1.93M | 1.99M | 1.04M | 766.96K | 715.44K | 747.30K | 682.94K | 561.01K | 543.42K | 512.45K | 363.18K | 206.89K | 223.98K | 195.60K | 191.83K | 293.85K | 261.15K | 503.76K | 632.09K | 139.86K | -100.00K |
| EBITDA | 11.80M | 12.57M | 18.49M | 14.70M | 11.85M | 13.31M | 11.72M | 10.38M | 9.17M | 7.68M | 5.48M | 4.84M | 4.67M | 4.52M | 3.79M | 2.59M | 2.72M | 3.02M | 1.20M | 503.32K | 850.21K | 1.46M | 691.94K | 91.90K | 24.49K | -205.28K | -1.70M | -1.03M | 100.00K |
| EBITDA Ratio | 16.85% | 14.64% | 27.66% | 24.65% | 28.50% | 39.54% | 43.98% | 43.15% | 45.95% | 32.97% | 38.36% | 48.90% | 46.74% | 37.88% | 34.12% | 26.98% | 29.43% | 33.96% | 19.85% | 10.40% | 16.33% | 26.68% | 15.57% | 2.35% | 0.60% | -10.25% | -61.53% | -30.75% | 3.85% |
| Operating Income | 6.13M | 8.73M | 11.34M | 7.86M | 8.89M | 10.65M | 10.30M | 8.26M | 7.23M | 5.86M | 4.44M | 4.07M | 3.61M | 3.60M | 2.87M | 1.81M | 2.18M | 2.50M | 833.14K | 296.43K | 626.23K | 1.27M | 500.11K | -201.95K | -236.66K | -709.05K | -2.18M | -1.17M | 200.00K |
| Operating Income Ratio | 8.76% | 14.64% | 21.03% | 16.92% | 21.38% | 31.35% | 34.71% | 34.24% | 36.21% | 31.98% | 38.74% | 40.44% | 38.23% | 30.72% | 26.80% | 19.82% | 24.29% | 28.26% | 14.23% | 6.24% | 12.03% | 23.07% | 11.25% | -5.16% | -6.52% | -20.45% | -82.58% | -46.90% | 7.69% |
| Total Other Income/Expenses | 6.28M | 2.97M | 204.00K | -168.00K | 2.50M | -92.73K | -158.85K | -24.02K | 4.59K | -163.60K | 73.93K | 184.41K | 342.77K | 169.40K | 233.87K | 214.83K | 268.03K | 121.69K | 55.64K | 51.69K | 72.40K | -7.44K | -13.60K | -22.05K | -19.34K | 133.98K | 116.84K | -305.99K | 0.00 |
| Income Before Tax | 12.41M | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M | 10.14M | 8.24M | 7.24M | 5.69M | 4.51M | 4.26M | 3.95M | 3.77M | 3.10M | 2.03M | 2.45M | 2.62M | 888.78K | 348.12K | 698.63K | 1.26M | 486.52K | -224.00K | -256.00K | -575.07K | -2.07M | -1.48M | 0.00 |
| Income Before Tax Ratio | 17.73% | 19.63% | 28.04% | 23.86% | 27.38% | 31.08% | 34.18% | 34.14% | 36.23% | 31.08% | 39.38% | 42.27% | 41.85% | 32.17% | 28.98% | 22.17% | 27.28% | 29.63% | 15.18% | 7.32% | 13.42% | 22.94% | 10.95% | -5.72% | -7.05% | -16.59% | -78.17% | -59.17% | 0.00% |
| Income Tax Expense | 2.46M | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M | 1.20M | 2.45M | 2.29M | 1.85M | 1.49M | 1.37M | 1.14M | 1.06M | 948.43K | 614.58K | 720.61K | 1.16M | 212.90K | 85.80K | -137.86K | -1.25M | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | -38.80K | 0.00 |
| Net Income | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M | 8.93M | 5.79M | 4.95M | 3.84M | 3.03M | 2.89M | 3.03M | 2.71M | 2.16M | 1.41M | 1.73M | 1.47M | 675.88K | 262.32K | 836.49K | 2.51M | 484.92K | -225.60K | -257.60K | -576.67K | -2.07M | -1.44M | 0.00 |
| Net Income Ratio | 14.22% | 16.72% | 23.16% | 21.05% | 22.44% | 25.27% | 30.12% | 23.98% | 24.79% | 20.98% | 26.40% | 28.66% | 32.05% | 23.16% | 20.13% | 15.44% | 19.24% | 16.55% | 11.54% | 5.52% | 16.07% | 45.69% | 10.91% | -5.76% | -7.10% | -16.63% | -78.23% | -57.62% | 0.00% |
| EPS | 0.50 | 0.50 | 0.62 | 0.49 | 0.52 | 0.49 | 0.52 | 0.34 | 0.29 | 0.23 | 0.19 | 0.18 | 0.19 | 0.17 | 0.14 | 0.09 | 0.11 | 0.10 | 0.05 | 0.02 | 0.06 | 0.18 | 0.04 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| EPS Diluted | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 | 0.08 | 0.10 | 0.08 | 0.04 | 0.02 | 0.05 | 0.17 | 0.03 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| Weighted Avg Shares Out | 19.99M | 20.08M | 20.20M | 20.05M | 17.82M | 17.49M | 17.33M | 17.24M | 17.03M | 16.86M | 16.17M | 16.00M | 15.76M | 15.54M | 15.83M | 16.13M | 16.13M | 15.28M | 14.72M | 14.44M | 13.98M | 13.64M | 13.63M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
| Weighted Avg Shares Out (Dil) | 20.30M | 20.47M | 20.75M | 20.74M | 18.54M | 18.06M | 17.86M | 17.52M | 17.21M | 17.03M | 16.41M | 16.32M | 16.15M | 16.08M | 16.51M | 17.19M | 18.14M | 17.96M | 16.29M | 15.92M | 15.58M | 14.96M | 14.10M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wednesday, April 5,...
Simulations Plus (SLP) Ties With IMB PAS for New Compounds
Simulations Plus (SLP) noted that any intellectual property arising from the collaboration, will be jointly owned by Simulations Plus and IMB PAS.
Simulations Plus to Present at Sidoti March Small-Cap Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking...
Simulations Plus to Present at Sidoti March Small-Cap Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O'Connor will be presenting at the Sidoti Small-Cap Investor Conference taking...
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, using its AI/ML technologies in ADMET Predictor, will partner with the Polish Academy of Sciences to design novel lead molecules.
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it entered into a collaborative research agreement with the Institute of Medical Biology of the...
Form 8.3 - REDX PHARMA PLC
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SOFINNOVA CROSSOVER I...
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians,...
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March...
Asia Pacific Substrate-Like PCB Market 2022: Sector to Reach $25 Billion by 2031 at a 15.6% CAGR – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Substrate-Like PCB Market 2021-2031 by Inspection Technology, Line/Space, Application, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. Asia Pacific substrate-like PCB (SLP) market will grow by 15.6% annually with a...
Source: https://incomestatements.info
Category: Stock Reports